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Abstract: Pancreatic islet transplantation is a promising treatment for type 1 diabetes mellitus
offering improved glycaemic control by restoring insulin production. Improved human pancreatic
islet isolation has led to higher islet transplantation success. However, as many as 50% of islets are
lost after transplantation due to immune responses and cellular injury, gene therapy presents a novel
strategy to protect pancreatic islets for improved survival post-transplantation. To date, most of
the vectors used in clinical trials and gene therapy studies have been derived from mammalian
viruses such as adeno-associated or retrovirus. However, baculovirus BacMam vectors provide
an attractive and safe alternative. Here, a novel BacMam was constructed containing a frameshift
mutation within fp25, which results in virus stocks with higher infectious titres. This improved
in vitro transduction when compared to control BacMams. Additionally, incorporating a truncated
vesicular stomatitis virus G protein increased transduction efficacy and production of EGFP and
BCL2 in human kidney (HK-2) and pancreatic islet  cells (EndoC H3). Lastly, we have shown
that our optimized BacMam vector can deliver and express egfp in intact pancreatic islet cells from
human cadaveric donors. These results confirm that BacMam vectors are a viable choice for providing
delivery of transgenes to pancreatic islet cells.
Keywords: BacMam; baculovirus; gene therapy; high-titre virus; human pancreatic islet cells
1. Introduction
Islets of Langerhans are micro-organs that comprise a cluster of cells consisting of
glucagon-secreting alpha cells, insulin-secreting beta cells, pancreatic polypeptide-secreting F
(or gamma) cells, somatostatin-secreting delta cells, and ghrelin-secreting epsilon cells [1,2].
The pancreas contains between 300,000 and 1.5 million islets, which contribute 1–2% of the total
pancreatic mass [3].
Type 1 diabetes mellitus (DM1), which has been diagnosed in an estimated 35 million patients
worldwide, is caused by auto-immune destruction of the pancreatic islet  cells and subsequent insulin
deficiency [3,4]. Although DM1 is less common than other type of diabetes, it remains a serious chronic
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disorder usually starting during childhood or adolescence [5]. Whilst in most people the disease
can be managed through daily injection of insulin, some suffer acute hypoglycaemic episodes that
may be life-threatening [6]. For these patients, one of the most promising therapies is pancreatic islet
transplantation as it is a minimally invasive treatment that has the potential to reverse DM1. This leads
to improved glycaemic control, abrogating the need for insulin in some patients [7,8].
Most islet recipients require more than one infusion to achieve insulin-independence as both
pancreatic islet isolation and survival after transplantation determine the success of the procedure [9].
Although some loss in yield occurs during pancreatic islet cell isolation, several studies have shown
that most of the losses occur due to pancreatic islet death in the post-transplant period [10,11].
Many cellular mechanisms contribute to pancreatic islet destruction following transplantation
including alloantigen-specific and immune-mediated destruction. However, most losses have been
attributed to inflammatory events caused mainly by ischemia-reperfusion injury (IRI) [12–14]. Damage
from IRI occurs when the blood supply returns to the tissue after a period of anoxia and nutrient
depletion [15]. Molecular oxygen, present in the restored blood supply, is the source of the reactive
oxygen species (ROS) responsible for inflammation and oxidative damage in transplanted tissue [16].
Previous studies have shown that apoptosis caused by IRI is responsible for the induction of
inflammation and subsequent organ damage. Moreover, it has been shown that suppression of
apoptosis can prevent inflammation and tissue injury [17,18].
It is possible that pre-transplantation gene therapy could be used to improve the outcomes of
pancreatic islet transplantation. Gene therapy involves the therapeutic delivery of specific gene(s)
into target cells and could be used as a tool to improve islet transplant success by delivering genes
that could reduce IRI, inflammation or inhibit apoptosis. Viruses are good candidates to be used as
gene therapy vectors as they have evolved to enter host cells and deliver genetic material for gene
expression. The majority of work in this field has utilised mammalian viruses such as adeno-associated,
retro and herpes viruses. However, there are safety concerns with using mammalian viruses due
to their natural pathogenicity and immunogenicity [19]. An alternative insect-specific virus vector
based on baculovirus does not have any of these safety concerns. In addition, there is no pre-existing
immunity to baculovirus unlike mammalian virus-based vectors [20].
Baculoviruses are arthropod-specific viruses widely used for high-yield protein production
in insect cells with most vectors based on the Autographa californica nucleopolyhedrovirus
(AcMNPV) [21]. These viruses are unable to replicate in mammalian cells as the viral promoters
are not active. However, the baculovirus can transduce a wide variety of mammalian cells and
express foreign genes when these are placed under the control of a mammalian promoter such as the
cytomegalovirus (CMV) immediate early 1 promoter. Baculovirus-based vectors for expression in
mammalian cells are referred to as BacMam [22–25].
The main disadvantage of the BacMam system is that relatively high ‘multiplicities of infection’
(100+ virus particles per cell) are necessary to deliver sufficient virus genomes into target cells for
effective transgene expression [26,27]. The input virus does not replicate so gene expression depends
solely on the number of genomes that enter the cell. Therefore, the BacMam virus can require either
concentration prior to the transduction or the use of chemicals to enhance gene expression, e.g., sodium
butyrate [28]. Concentration of virus is possible but time-consuming and labour intensive. The use of
chemical enhancers may have side effects on cell metabolism, which will be undesirable if the intended
use of the BacMam is gene therapy.
Here, we report the construction of a novel BacMam virus that contains a mutation within fp25,
which comprises the insertion of an additional adenine that causes a frame-shift in the coding region,
truncating the native FP25 protein [29]. When using baculovirus vectors in insect cells, this mutation is
undesirable as it reduces expression from the polyhedrin gene promoter due to a decrease in the rate
of transcription [30]. Conversely, however, this mutation has also been shown to enable production of
virus stocks with consistently very high infectious titres [29,31]. In this study, we evaluate the benefits
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of incorporating the fp25 ‘high-titre’ (HT) mutation into a BacMam genome for the transduction of
mammalian cells.
The molecular mechanisms involved in BacMam entry into mammalian cells remain poorly
characterized. However, despite this, some studies have demonstrated that BacMam transduction
efficacy can be significantly improved by displaying different proteins on the baculovirus budded
virus (BV) surface [32,33]. In the current study, we combined the fp25 HT mutation genome with
pseudotyping the baculovirus envelope with a truncated vesicular stomatitis virus-G (VSV-G) protein.
The benefits of this new vector for mammalian cell transduction and gene expression was evaluated in
cell culture and in human pancreatic islet cells.
2. Materials and Methods
2.1. Cells, Plasmids and Viruses
2.1.1. Cells
Insect cell lines Spodoptera frugiperda Sf9 [34] and Sf21 [35] were maintained at 28 C using ESF921
media (Expression Systems) or TC100 media supplemented with 10% (v/v) foetal calf serum (Thermo
Fisher Scientific, Loughborough, UK; TFS), respectively. HK-2 cells were purchased from American
Type Culture Collection and cultured in Keratinocyte serum-free medium (KSFM; GLT) supplemented
with human recombinant Epidermal Growth Factor 1-53 (EGF 1-53) and Bovine Pituitary Extract (BPE).
Cells were incubated at 37 C with 5% (v/v) CO2. The EndoC-H3® cell line was purchased from
Univercell-Biosolutions, Toulouse, France (U-B) and cultured according to the user’s guide in OPTl1®
media (U-B) containing 5 g/mL puromycin [36]. Cells were seeded onto COAT®-treated TPP®
tissue culture flasks (U-B) at 7  104 cells/cm2.
2.1.2. Transfer Plasmid Construction
To generate the pCMV.EGFP plasmid, egfp was excised from pEGFP-N1 (Clontech, Mountain
View, CA, USA) with restriction endonucleases NotI and EcoRI and inserted into pOET6-BacMam,
which contains the CMV immediate-early 1 enhancer promoter (Oxford Expression Technologies,
Oxford, UK; OET). For pCMV.BCL2, bcl2 was PCR amplified from a synthetic gene (GeneArt™) to
introduce EcoRI and XbaI sites at the 50 and 30 ends, respectively, and also inserted into pOET6-BacMam.
pAcCMV.EGFP_VSV-G was generated in several steps. The pEGFP-N1 was modified by inserting
an XbaI linker into the unique AseI site. The CMV promoter-EGFP gene cassette was then removed
from this vector with XbaI and NotI and inserted into pAcUW21 [37] previously modified to include a
NotI site between unique XbaI and BglII sites. A 678 bp synthetic sequence comprising the AcMNPV
polyhedrin gene (polh) promoter and gp64 signal peptide coding region linked with the truncated
version of VSV-G [32] was then inserted between the XbaI and SwaI sites of this vector to create
pAcCMV.EGFP_VSV-G.
2.1.3. BacMam Production
Recombinant BacMam were prepared by mixing transfer plasmids with either flashBAC™ or
BacPAK6HT virus DNA and transfecting Sf9 cells as recommended by the supplier (OET). After 5 days
of incubation at 28 C, the cell media containing budded viruses were harvested and stored at 4 C.
BacMams for generating high titre viruses were prepared by first constructing BacPAK6HT. This was
achieved by co-transfecting AcdefrTp35r [29] with pBacPAK6 and selecting a recombinant virus with
a copy of the -galactosidase coding region under the control of the polh promoter essentially as
described previously [38]. Virus DNA was extracted from BacPAK6HT, digested with Bsu36I and
mixed with transfer vectors prior to co-transfecting Sf9 cells. Recombinant BacMam were selected and
plaque purified to genetic homogeneity [38].
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2.1.4. Virus Amplification
Additional passages of the virus stocks were amplified in Sf9 cells as previously described [39].
Sf9 cells were seeded at a density of 1.5–2  106 cells/mL in a shake culture, and then infected with
the virus at a multiplicity of infection (MOI) of 0.1 pfu/cell and incubated for 5 days at 28 C on a
shaking platform. After incubation, the culture was harvested and centrifuged at 4000 rpm for 15 min
at 4 C (TY-JS 4.2 rotor, J6-MI Beckman centrifuge) to remove cell debris. The clarified culture medium
containing BV was stored in aliquots at 4 C.
2.1.5. Titration of Virus Infectivity
Baculoviruses stocks were titrated either using a conventional method based on a plaque
assay [39] or more rapidly with a quantitative polymerase chain reaction technique (baculoQUANT™)
as described by the manufacturer (OET).
2.2. Gene Delivery in Mammalian Cells Using BacMam Virus Vectors
2.2.1. In Vitro Gene Delivery
One mL HK-2 cells were seeded at a concentration of 1  105 cells/mL in a 12-well plate and
incubated overnight at 37 C. The cells were then washed with sterile phosphate buffered saline (PBS)
and transduced with BacMam viruses at a MOI of 150 pfu/cell and incubated for 5 h at 37 C. The virus
inoculum was then replaced with growth medium and the cells were returned to 37 C for the required
time. EndoC-H3 cells were seeded onto COAT® (U-B) treated 12-well plates at 2.5  105 cells/well.
The following day, cells were washed with sterile PBS and then transduced with BacMam viruses
using a MOI of 250 pfu/cell and incubated for 5 h at 37 C. The virus inoculum was then replaced
with growth medium and cells were returned to 37 C for the required time. Inducible excision of
CRE-mediated immortalizing transgenes was performed with addition of 4-Hydroxy Tamoxifen (1 M)
for 3 weeks prior to transductions.
2.2.2. Ex Vivo Donor Islet Cells
Islet cells were supplied by the Diabetes Research and Wellness Foundation (DRWF) human islet
isolation facility, Churchill Hospital, Oxford in cold storage media. On arrival, an estimation of the
total cell numbers was calculated from a small aliquot. The islets were then re-suspended in fresh
medium (CRML media (Gibco™) containing L-Glutamine (1) and 2% human albumin), seeded at a
concentration of 1  105 cells/well in a 12-well plate and incubated for 1 h at 37 C with 5% (v/v) CO2
to recover. The islets were then directly transduced using a MOI of 150 pfu/cell and the incubation
continued for up to 48 h after transduction.
2.3. Fluorescence Microscopy
Fluorescence microscopy was performed on in vitro and ex vivo samples at different time points
using a Zeiss Axiovert 135 inverted epifluorescence microscope (Cambridge, UK) with a 10 Plan
Neofluar objective lens and 10 ocular lens. For EGFP detection, a band pass 546 filter was used.
2.4. Fractionation of Budded Virus Envelope
Separation of purified BV into envelope and capsid fractions was performed essentially as
previously described [40]. Briefly, purified BV particles were re-suspended in 1% (v/v) NP-40 for
30 min and then the capsid fraction was separated by centrifugation.
2.5. SDS-PAGE and Immunoblot Analysis
Proteins were separated on 4–20% mini-PROTEAN®TGX™ pre-cast protein gels (Bio-Rad,
Watford, UK; B-R) and transferred onto a polyvinylidene diflouride (PVDF) membrane using a
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Trans-Blot®Turbo™ transfer pack (B-R). Following the transfer, membranes were incubated in 5%
powdered milk (Marvel®) dissolved in PBST (1 PBS containing 0.1% (v/v) Tween20) and agitated at
room temperature for 1 h to prevent non-specific binding. Subsequently, membranes were treated with
either rabbit polyclonal EGFP, mouse monoclonal actin (Abcam, Cambridge, UK), mouse monoclonal
BCL2 (Santa Cruz, Dallas, TX, USA) or rabbit monoclonal VSV-G (Abcam) primary antibodies for
1 h. Membranes were washed 4  10 min with PBST and incubated with a species-specific secondary
antibody conjugated with horseradish peroxidase for 1 h. To remove any background, membranes
were washed 4  10 min with PBST. Bound proteins were visualized using Clarity™ Western ECL
blotting substrates (B-R). After a 5 min incubation, the bands were imaged using a ChemiDoc™MP
imaging system (B-R). The band intensities for actin (ai) were used as an internal reference for each
sample to calculate the amount of synthesis of either protein targets (ti) EGFP or BCL2 (ai/ti  100),
expressed as a percentage increase.
2.6. Statistical Analysis
All data were analysed using GraphPad Prism Version 7 for Windows (GraphPad Software Inc.,
La Jolla, CA, USA) with results displayed in  SD. Statistical analysis were performed using t-test,
with a p-value of < 0.05 considered statistically significant.
2.7. Flow Cytometry
Flow cytometry was used to provide a quantitative measure of percentage transduced cells and the
intensity of the signal within cells. Green fluorescence from in vitro and ex vivo BacMam-transduced
cells, harvested at different time points, were analysed using a Novocyte 3000 Flow Cytometer
(ACEA Biosciences, San Diego, CA, USA) according to the manufacturer’s instructions. Negative gates
were set using the data from mock-transduced cells.
2.8. Confocal Microscopy
BacMam-transduced islet cells were washed twice in PBS before fixation for 45 min at room
temperature with 4% formaldehyde in PBS. The fixative was removed and islets were washed twice in
PBS prior to being re-suspended in Vectashield mounting medium with DAPI (Vector Laboratories,
Peterborough, UK) onto glass slides. The fixed islets were covered with glass cover slips and stored
at 4 C until imaging. Images were acquired using an oil immersion objective (Plan-Apochromat
63X, 1.4 numerical aperture) attached to a Zeiss LSM 880 laser scanning microscope. Post-acquisition
image processing and Z-stack image projections were processed using ZEN black software (Zeiss,
Cambridge, UK).
3. Results
3.1. Enhancing Infectious Budded Virus Production Using BacMam with a Mutation in fp25
Baculoviruses are able to enter mammalian cells and express foreign genes placed under the
control of a mammalian gene promoter in a process known as transduction (Figure 1A). To explore
the feasibility of using these vectors for ex vivo gene therapy of pancreatic islet cells, BacMam viruses
expressing enhanced green fluorescent protein (egfp) under the control of the CMV immediate early
1 promoter were generated to observe and monitor transduction efficacy. An additional virus vector
encoding an anti-apoptotic gene B-cell lymphoma-2 (bcl2) was constructed to investigate the expression
of a therapeutic gene using the BacMam system (Figure 1B).
The BacMam vectors generated in this study were based on two parental virus genomes.
The first comprised flashBAC™ (FB), normally used to make recombinant viruses for expression
of genes in insect cells. The second contained a single nucleotide insertion in fp25, which results in a
frame-shift mutation that introduces an early stop codon into the coding region of the gene (Figure 1B).
This mutation has been shown to decrease polyhedra formation and increase BV production [30,41].
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Hence, this virus was designated high-titre (HT). To explore the effect of this mutation on BV production
by recombinant BacMam vectors, ten different FB and HT viruses were prepared and their infectivity
determined. The average titres for the FB and HT viruses were 1.09  108 and 4.07  108, respectively.
This four-fold increase in the average infectious titre for the HT viruses was shown to be statistically
significant (Figure 1C).
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Figure 1. (A) schematic representation of Bac am mediated gene delivery into mammalian cells
(transduction). Budded viruses are taken up by endocytosis and released into the cytoplasm.
The nucleocapsids are directed to the nucleus where the DNA is released for transcription under
the control of a mammalian promoter and the resultant mRNA is then translated into the recombinant
protein; (B) schematic representation of flashBAC™ (FB) and high-titre (HT) egfp and bcl2 BacMam
vectors. The fp25 mutation results from the insertion of an adenine causing a frameshift and an early
stop codon (red letters); (C) comparison of the infectious titres from 10 FB and HT BacMam viruses as
determined by plaque assay. Results were plotted using Graphpad Prism (error bars represent  SD)
and analysed using a Student’s t-test (p < 0.05).
3.2. Improving BacMam-Mediated Gene Expression in Mammalian Cells
In order to compare transduction efficacy between the FB and HT BacMam vectors, expression
of egfp and bcl2 was first evaluated in human kidney (HK-2) cells using CMV.EGFPFB, CMV.EGFPHT,
CMV.BCL2FB or CMV.BCL2HT. A null virus (CMV.NULLHT), lacking a gene under the CMV immediate
early gene promoter, and mock-transduced cells, were included as negative controls in all experiments.
Transductions were carried out in triplicate and recombinant protein production was evaluated by
fluorescent microscopy, flow cytometry and Western blotting using target-specific antibodies. Initial
comparisons between CMV.EGFPFB- and CMV.EGFPHT-transduced HK-2 cells using fluorescence
microscopy showed that egfp expression was detected at 24 h post-transduction (hpt) and continued to
increase up to 72 hpt (Figure 2). A greater number of cells, and a higher intensity of fluorescence within
cells, was observed in transductions with CMV.EGFPHT compared with CMV.EGFPFB (Figure 2).
To provide a quantitative measure of transduction efficacy, CMV.EGFPFB- or CMV.EGFPHT-transduced
HK-2 cells were analysed using flow cytometry. Interestingly, these results (Table 1) demonstrated that by
24 hpt, a high percentage of cells had been successfully transduced by both CMV.EGFPFB (90%  1.6)
and CMV.EGFPHT (95%  0.97). By 48 hpt, almost all cells (99%) showed evidence of successful
transduction with either the FB or HT vector. However, the intensity of EGFP fluorescence in
CMV.EGFPHT-transduced HK-2 cells was higher than those transduced with CMV.EGFPFB, as shown
by a higher proportion of cells with a fluorescein isothiocyanate (FITC) reading above 107 (Table 1) at
all times points after transduction. Overall, these results suggest that BacMam vectors incorporating
the HT mutation do not enhance the proportion of cells transduced, but, instead, may help deliver
more copies of the target gene per cell, which results in increased recombinant protein production
(in this case, EGFP).
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Table 1. Quantitative assessment of BacMam transduction of HK-2 cells by flow cytometry.
24 h Post-Transduction 48 h Post-Transduction 72 h Post-Transduction
FB 1 HT 2 FB 1 HT 2 FB 1 HT 2
% transduced HK-2 cells 90 95 99 99 99 99
% transduced HK-2 cells with
FITC 3 reading above 107 21 42 21 47 10 27
1 FB = CMV.EGFPFB; 2 HT = CMV.EGFPHT, 3 Fluorescein isothiocyanate.Viruses 2018, 10, x FOR PEER REVIEW  7 of 17 
 
 
Figure 2. Representative images of bright (lower panels) and fluorescent (upper panels) fields of HK-
2 cells transduced with CMV.EGFPFB (FB) or CMV.EGFPHT (HT) BacMam viruses at ‘multiplicity of 
infection’ of 150. Images were taken 24, 48 and 72 hpt using a Zeiss Axiovert 135 inverted 
epifluorescence microscope (10×). Duplicate images are shown for each virus and time point. Scale-
bar, 50 nm. 
To investigate any difference in recombinant protein production between the normal and HT 
BacMam vector, immunoblot analysis was performed on transduced HK-2 cell lysates harvested at 
72 hpt (Figure 3A(i,ii)). This analysis demonstrated that the production of both EGFP and BCL2 was 
increased in HK-2 cells transduced with the HT BacMam vector in comparison to those transduced 
with the unmodified vectors. To semi-quantify these results, band densitometry was performed using 
a β-actin loading control for standardisation (Figure 3B(i,ii)). This demonstrated a statistically 
significant increase in protein production of approximately 25% (EGFP; Figure 3Bi) and 50% (BCL-2; 
Figure 3Bii) when HK-2 cells were transduced with CMV.EGFPHT and CMV.BCL2HT, respectively.  
To confirm whether the HT BacMam was the more suitable vector for gene delivery, it was 
pertinent to replicate the experiments in other cell lines. For the interests of this study, a human 
derived pancreatic beta cell line (EndoC-βH3) was selected, which would also provide an early 
indication of donor islet cell susceptibility to BacMam vectors. In addition, it was crucial to test 
whether the therapeutic gene target bcl2 could be expressed in a pancreatic beta cell line. Therefore, 
EndoC-βH3 cells were transduced with CMV.BCL2FB or CMV.BCL2HT and harvested at 72 hpt (Figure 
3Aiii). Western blot analysis confirmed the production of BCL2 and band densitometry analysis 
demonstrated an approximately 50% increase in protein yield using the HT vector in comparison to 
FB (Figure 3Biii). This provides further evidence that a BacMam vector based on the HT virus genome 
may be the more suitable choice to achieve improved gene delivery. 
Figure 2. Representative images of bright (lower panels) and fluorescent (upper panels) fields of
HK-2 cells transduced with CMV.EGFPFB (FB) or CMV.EGFPHT (HT) BacMam viruses at ‘multiplicity
of infection’ of 150. Images were taken 24, 48 and 72 hpt using a Zeiss i ert i erte
ifl r sce ce microscope (10). uplicate images are shown for each virus and time point. Scale-bar,
50 nm.
i
ified vectors. o se i-quantify these results, band densitometry was performed using a
-actin loading contr l for standardisation (F gure 3B(i,ii)). This demon trated a atistically significant
increase in prot in produc io of approximately 25% (EGFP; Figure 3Bi) and 50% (BCL-2; Figure 3Bii)
when HK-2 cells were transduc d with CMV.EGFPHT and CMV.BCL2HT, respectively.
fi
t to replicate the xperiments in other c ll lines. For the interests of this study, a human derived
pancr atic beta cell line (EndoC-H3) was selected, whi h would also provide an early indication
of donor islet cell susceptibi ity to BacMam vectors. In addition, it was crucial to test whether the
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therapeutic gene target bcl2 could be expressed in a pancreatic beta cell line. Therefore, EndoC-H3
cells were transduced with CMV.BCL2FB or CMV.BCL2HT and harvested at 72 hpt (Figure 3Aiii).
Western blot analysis confirmed the production of BCL2 and band densitometry analysis demonstrated
an approximately 50% increase in protein yield using the HT vector in comparison to FB (Figure 3Biii).
This provides further evidence that a BacMam vector based on the HT virus genome may be the more
suitable choice to achieve improved gene delivery.Viruses 2018, 10, x FOR PEER REVIEW  8 of 17 
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Figure 3. ( ) i u o l t a al sis of cel lysates fol o ing transducti it the na ed Bac a
vector in -2 ( i, i ) or Endo - ( iii) ll t t i i-
olecular weight markers are in kDa. (B) A bar graph was constructed using GraphP d Prism to how
the relative band intensities for (Bi) EGFP in HK-2, (Bii) BCL2 in HK-2 and (Biii) BCL2 in Endo -H3
cells btained by band densitometry. Each sa ple was normalis d agai st a -actin loading control.
Error bars represent  SD (n = 3) a d indicate a significa t diff rence between CMV.EGFPFB and
.EGFPHT, or C V.BCL2FB and . HT transduced cells usi g a Student’s t-test (p < 0.05).
3.3. Pseudotyping Virus Particles with Truncated Vesicular Stomatitis Virus G-Protein to Enhance
Transduction Efficacy
It has been shown that pseudotyping of viral vectors can be employed to enhance transduction
of particles into cells [42,43]. Incorporation of a truncated VSV-G into the baculovirus BV membrane
has been shown to increase transduction efficacy up to 15-fold in vivo and in vitro [32]. To demonstrate
whether VSV-G pseudotyping might have a similar effect on BacMam based on the HT genome,
an additional vector was generated by inserting the truncated VSV-G gene under control of the
polh promoter (Figure 4A(i,ii)). Incorporation of VSV-G into the BV envelope was confirmed by
separating purified BV into nucleocapsid and envelope fractions, followed by immunoblot analysis
using anti-VSV-G specific antibody (Figure 4Aiii).
The potential benefit of VSV-G pseudotyping was tested by transducing HK-2 (150 MOI) and
EndoC-H3 (250 MOI) cells with CMV.EGFPHT or CMV.EGFPHT_VSV-G viruses (Figure 4B(i,ii)).
Transduced cells were analysed at 72 hpt using fluorescence microscopy and Western blotting.
Fluorescence microscopy showed that CMV.EGFPHT_VSV-G virus both increased the percentage
of cells transduced and the intensity of EGFP fluorescence, when compared to the non-pseudotyped
virus, in both cell lines tested (Figure 4B(i,ii)). This difference was more evident for EndoC-H3
cells, where a very low level of egfp expression was detected when the cells were transduced with
CMV.EGFPHT. In contrast, the pseudotyped vector resulted in considerably higher egfp expression.
No egfp expression was detected in mock- and CMV.NULLHT-transduced cells (Figure 4B(i,ii)).
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Immunoblot analysis supported the results observed with fluorescence microscopy; an increase
in protein yield was detected from the VSV-G-pseudotyped vector-transduced cells (Figure 4C(i,ii)).
As described earlier, this was further confirmed by band densitometry where EGFP synthesis by
different recombinant viruses was assessed in comparison to an internal actin control. There was an
increase in EGFP production of approximately 160% in HK-2 cells (Figure 4Di) and 20% in EndoC-H3
cells (Figure 4Dii).Viruses 2018, 10, x FOR PEER REVIEW  9 of 17 
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(Ai) 21-amino-acid ectodomain of VSV-G, with its transmembrane and cytoplasmic tail domains
(aa 442–511) [29] was inserted into the HT virus genome under the control of the polh promoter
as a fusion to the gp64 signal peptide. TAG, stop codon (red) (Aii) Schematic representation
of the BV article with VSV-G incorporation in th envelope surface alongside the native GP64
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using a Student’s t-test (p < 0.05).
3.4. In Vitro Expression of egfp in a Non-Proliferative Human Beta Cell Line
The EndoC-H3 cells were treated with tamoxifen to remove the CRE-mediated immortalising
transgenes. After treatment, the cells become functional non-proliferative human  cells that
closely represent the characteristics of pancreatic  cells and thus represent a more realistic model
for pancreatic islets [36]. Due to the scarcity of donor islets, this provided an alternative model
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for studying the BacMam system in relation to successful gene delivery in pancreatic  cells.
Both tamoxifen-treated and non-treated EndoC-H3 cells were transduced, in duplicate, with the
BacMam virus CMV.EGFPHT_VSV-G (Figure 5). Fluorescence microscopy and Western blot analyses
of egfp expression at 48 hpt demonstrated that there was no decrease in the transduction susceptibility
of the non-proliferating  cells to CMV.EGFPHT_VSV-G (Figure 5A,B).
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Figure 5. (A) bright field (left) and fluorescenc ( i t) i ages of tamoxifen-treated (4-OHT) and
untreated EndoC-H3 cells transduced with .E FP T_VSV-G at MOI 250. Treated cells were
incubated with tamoxifen for three weeks prior to transduction to remove the CRE-mediated
immortalising transgenes. Images were taken at 48 hpt using a Zeiss Axiovert 135 inverted
epifluorescence microscope (10). Scale bar, 100 nm. (B) Tamoxifen-treated or untreated EndoC-H3
cells were transduced with the indicated BacMam vectors or controls (in duplicate) and were harvested
at 48 hpt for analysis by Western blotting using EGFP-specific antibody. -actin was used as a loading
control. Molecular weight markers are in kDa.
3.5. BacMam Mediated Gene Expression in Human Pancreatic Islet Cells from Cadaveric Donors
Islets from two different cadaveric donors were transduced ex vivo with four different
egfp-expressing BacMam vectors (CMV.EGFPFB, CMV.EGFPHT, CMV.EGFPFB_VSV-G and
CMV-EGFPHT_VSV-G) using MOI 250 for each (Figure 6). The islets were monitored over
48 h and visual examination after BacMam-transduction did not appear to impact cell viability or
cause the islet clusters to break apart. Fl ores ence microscopy analysis demonstrated that egfp
expression could be detected in transduced cells from all four vector versions at 48 hpt (Figure 6A).
Partial auto-fluorescence w s observed in both mock- and CMV.NULLHT-transduced samples
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(Figure 6A), however, this was likely a result of poor cell quality and/or cell stress, and was negligible
in comparison to fluorescence associated with BacMam EGFP virus vectors (Figure 6A).
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Figure 6. (A) human pancreatic islets isolated fro cadaveric donor 1 (Ai) and donor 2 (Aii) were
transduced with BacMam viruses at 250 MOI as shown. Bright field (left) and fluorescent (right) images
were taken at 48 hpt using a Zeiss Axiovert 135 inverted epifluorescence microscope (10). Scale bar,
100 nm. (B) Cell lysates were harvested from donor 1 (Bi) and donor 2 (Bii) at 24 and 48 hpt and were
analysed by Western blotting using EGFP-specific antibodies. Molecular weight markers are in kDa.
The difference in egfp expression levels observed between the standard FB and HT virus vectors
was minimal. However, a marked increase was observed when either of the VSV-G-pseudotyped
vectors (CMV.EGFPFB_VSV-G or CMV.EGFPHT_VSV-G) was used (Figure 6A). These initial
observations from the two sets of islets suggested that pseudotyping the baculovirus BV with
VSV-G results in improved gene delivery. To obtain a quantitative measure of this suggested
improvement, CMV.EGFPHT- or CMV.EGFPHT_VSV-G-transduced islet cells from the second
cadaveric donor were analysed by flow cytometry. The results indicated that at 48 hpt, 23.87%
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of the CMV.EGFPHT-transduced cells contained detectable EGFP compared to 34.64% of the
CMV.EGFPHT_VSV-G-transduced cells.
In addition to the fluorescence microscopy and flow cytometry analyses, immunoblotting was
carried out on transduced islets harvested at 24 and 48 hpt to assess the level of EGFP production.
A stained gel was also performed on samples to ensure equal loading (data not shown). These
results confirmed that the highest EGFP yield was obtained with CMV.EGFPHT_VSV-G at 48 hpt
(Figure 6B). In addition, the lower EGFP yield obtained with CMV.EGFPFB_VSV-G compared with
CMV.EGFPHT_VSV-G pseudotyped virus strengthens a role for the HT virus genome in improving
transduction outcomes (Figure 6B). The absence of EGFP by immunoblotting for CMV.EGFPFB and
CMV.EGFPHT is likely due to levels of EGFP being too low for detection.
As the islets comprised clusters of several hundred cells, and the flow cytometry analysis had
indicated that only about one-third of cells, maximally, were transduced with BacMam, we were
interested in understanding further the distribution of transduced cells within the islet cluster.
Therefore, three-dimensional analysis of CMV.EGFPFB or CMV.EGFPFB_VSV-G transduced islets was
undertaken using confocal microscopy (z-stack function). The results (Figure 7) indicated considerable
variation in the numbers of egfp expressing cells per islet for both CMV.EGFPHT (Figure 7A(i,ii)) and
CMV.EGFPHT_VSV-G (Figure 7B(i,ii)) at 48 hpt. This disparity is most likely related to the BacMam
viruses being unable to infiltrate the inner cells of the larger islets.
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Figure 7. Human pancreatic islets isolated from cadaveric donor 2 were transduced with (A)
CMV.EGFPHT or (B) CMV.EGFPHT_VSV-G BacMam viruses at 250 MOI (two representative images
are presented for each). Confocal microscopy images were taken at 48 hpt using a Zeiss LSM 880 laser
scanning microscope (63) and Z-stack image projections were processed using ZEN black (Zeiss,
Cambridge, UK). Green = EGFP, Blue = DAPI.
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4. Discussion
Pancreatic islet transplantation is being increasingly used as a treatment option for patients
with severe DM1. This treatment uses purified donor islet cells that are transplanted into the
hepatic portal circulation to promote engraftment. After surgery, the islet cells have been shown
to offer improved glycaemic control through restoration of insulin production [44]. However, islet
cell transplantation is limited by post-transplantation factors that can impact islet survival and
longevity. These include graft rejection, blood-mediated inflammatory reaction and hypoxia [13].
Viruses have been adapted to efficiently deliver therapeutic genes [45] and to modify islets for
improved survival post-transplantation [44,46]. The development of mammalian viral vectors capable
of transferring therapeutic genes has already been used for a variety of metabolic disorders and
autoimmune diseases [47], which account for 70% of clinical trials and gene therapy studies [40].
For islet transplantation, adeno-associated virus (AAV) has been evaluated due to its safety profile,
broad cell tropism and accessibility of established helper cell lines for vector production [44,45,48,49].
However, AAV vectors are limited by a maximum size gene insert of <4.5 kb and scale-up issues
resulting from difficulties in generating high-titres of virus [45,48]. Furthermore, mammalian virus
vectors still pose several problems regarding pre-existing immunity in the patient and the resulting
toxicity caused by adverse immune responses [50]. Therefore, this study investigated the use of
baculoviruses, which are non-pathogenic and replication-incompetent in humans, to overcome the
obstacles posed by currently used viral vectors [28,50–52]. In addition, this study demonstrates the
development of a new BacMam vector that could be used to efficiently transfer therapeutic genes into
human pancreatic islet cells.
The BacMam system requires relatively high MOI for effective transduction of mammalian cells.
Therefore, to overcome this shortcoming, a BacMam vector that contains a mutation within fp25, which
results in the production of infectious BV titres consistently above 3.0  108 pfu/mL was developed.
A BacMam vector with increased BV titre (HT BacMam) reduces the total volume of virus inoculum
to be scaled-up and minimises the need for virus concentration protocols to reach the high MOI
required for transduction. This could have future benefits resulting from reduced production and
scale-up costs. The increased virus titres observed in this study were similar to previous findings,
which indicates that the placement of a foreign gene under the CMV promoter did not impact the fp25
mutant phenotype [30]. This phenotype has been attributed to a failure to shift from BV production to
occlusion derived virus during the later phases of baculovirus infection, resulting in the continued
production of BV [30,41].
The initial in vitro transduction experiments using two distinct cell lines, HK-2 and EndoC-H3,
demonstrated an increase in gene delivery for the HT BacMam viruses when compared to the standard
(FB) BacMam viruses. Given the cells were transduced with equal MOI for both HT and FB viruses,
the increased expression levels are likely to relate to improved BV entry or gene delivery to the nucleus.
A previous study demonstrated that the fp25 mutation enhanced infectivity of the BV resulting from
better genome integrity and uptake [41]. This could suggest that the entry pathway used by the
baculovirus BV is similar in both mammalian and insect cells.
In this study, we investigated whether gene delivery with the HT BacMam vectors could be
improved further by pseudotyping BV with a truncated VSV-G protein. Use of VSV-G was based on
previous studies that reported enhanced transduction efficiency using baculovirus-mediated viral
vectors with in vitro and in vivo applications [32,42,50,53,54]. The results demonstrated that the VSV-G
pseudotyping did improve both the percentage of cells transduced and the EGFP signal intensity
in both HK-2 and EndoC-H3 cells. The absence of detectable EGFP protein by immunoblot in
EndoC-H3 using the non-pseudotyped HT BacMam vector confirms a beneficial role for VSV-G
during transduction. These observations are in agreement with previous findings, which indicated that
improved cell entry was a major factor for transduction efficiency [32,50]. Pseudotyped baculoviruses
expressing either influenza virus neuraminidase, Spodoptera exigua MNPV F protein or human
endogenous retrovirus envelope protein have also resulted in better cell entry [50]. Furthermore,
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increased expression could be enhanced from improved endosomal escape in a VSV-G pseudotyped
baculovirus [32].
To gain insight into the feasibility of transducing non-proliferating pancreatic  cells, EndoC-H3
cells were treated with tamoxifen. Overall, the results showed that the gene delivery and expression of
egfp was comparable between tamoxifen-treated and non-treated EndoC-H3 cells when transduced
with CMV.EGFPHT_VSV-G. This suggests that non-proliferative human beta cells are susceptible to
baculovirus transduction and can be targeted for gene therapy using BacMam vectors.
However, the pancreatic islet consists of several different types of cells clustered together and
the accessibility of these cells to the BacMam vector will be different to that of monolayer cultures
maintained within a laboratory setting. Therefore, to study the BacMam vector as a tool to efficiently
deliver genes in pancreatic tissue, we acquired islets that were isolated from cadaveric donor pancreases.
The results demonstrated that the BacMam vectors could successfully transduce intact islets from two
different donors. Interestingly, the pancreatic islets transduced with CMV.EGFPHT_VSV-G showed the
highest egfp expression compared to all other BacMam vectors tested in this study. These findings are
consistent with previous data within this study for transduced HK-2 and EndoC-H3 cells. To our
knowledge, this is the first evidence of ex vivo gene delivery in intact human pancreatic islet cells using
BacMam, progressing from a previous study characterising egfp expression in dispersed islet cells [55].
Although we have demonstrated the promise of a comparatively safe baculovirus-based gene
delivery system, further understanding will be required to optimise routes of administration and
understand the possible limitations that could arise from translation into clinical application. These
challenges include low transduction efficiency, inflammatory response and nonspecific gene delivery
along with understanding of the logistical, economic and clinical aspects [50].
5. Conclusions
In summary, our findings demonstrate a novel baculovirus-based delivery tool for therapeutic
genes that can be used in future, to potentially improve success rates of islet cell transplantation. Using
this system, we will further our study to characterise the therapeutic effects of delivering bcl2, sod2 and
anti-inflammatory genes into human pancreatic islet cells.
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